Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2011
Ardea Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 1-33734 | 94-3200380 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
4939 Directors Place San Diego, California | 92121 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (858) 652-6500
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Table of Contents
Table of Contents
| Item 7.01. | Regulation FD Disclosure |
On September 7, 2011, Ardea Biosciences, Inc. (the “Company”) issued a press release regarding its End-of-Phase 2 meeting with the U.S. Food and Drug Administration relating to lesinurad, the Company’s product candidate for the treatment of gout. A copy of the press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.
A copy of related presentation materials used by the Company at investor presentations from time to time is filed as Exhibit 99.2 to this Form 8-K. The Company does not intend to file any update of these presentation materials in the future. The fact that these presentation materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials.
The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
Exhibit | Document Description | |
| 99.1 | Press release dated September 7, 2011. | |
| 99.2 | Ardea Biosciences, Inc. presentation materials dated September 7, 2011 and to be used from time to time thereafter | |
Table of Contents
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ARDEA BIOSCIENCES, INC. | ||
| Date: September 7, 2011 | /s/ CHRISTIAN WAAGE | |
| Christian Waage | ||
| General Counsel | ||
Table of Contents
Exhibit | Document Description | |
| 99.1 | Press release dated September 7, 2011. | |
| 99.2 | Ardea Biosiences, Inc. presentation materials dated September 7, 2011 and to be used from time to time thereafter | |